Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes

Description

While metformin remains the first line treatment in most cases, choices for second line treatment now extend beyond sulfonylureas and include the sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon‐like peptide 1 (GLP1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors.

Authors

Renata Libianto, Timothy ME Davis, Elif I Ekinci

Learning Outcomes

  • Explain key components of the review.
  • List main recommendations.
  • Recognise changes in management as a result of the review.

Medical Journal of Australia
N/A
Reading: journal; textbook; book; literature review
1h : 0m
MBA: 1h : 0m
Endocrine System Diseases
Medical Practitioner, Medical Student, Doctor-in-Training, Non-Vocationally Registered, Researcher, Retired, Specialist - Other, Specialist General Practitioner
You have to be logged in to see the content of this module.

Provided by

doctorportal Learning respectfully acknowledges Aboriginal and Torres Strait Islander peoples as the first inhabitants of Australia. We respect the traditional owners of lands across Australia in which our members and staff work and live, and pay respect to their elders past, present and future.